0.00Open2.30Pre Close0 Volume24 Open Interest2.00Strike Price0.00Turnover756.28%IV3.37%PremiumDec 20, 2024Expiry Date2.16Intrinsic Value100Multiplier23DDays to Expiry0.14Extrinsic Value100Contract SizeAmericanOptions Type0.9097Delta0.0205Gamma1.29Leverage Ratio-0.0286Theta0.0004Rho1.17Eff Leverage0.0017Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet